| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Operating Officer
2 companies
Kevin Young last filed a Form 4 in June 2020, as Director at QNCX. The filings on record cover 2 companies. Kevin Young's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 25,612 shares of GILD.
Kevin Young has 8 Form 4 filings on record from May 2017 to June 2020, across 2 companies: Director at Quince Therapeutics (QNCX), 2019–2020; Chief Operating Officer at Gilead Sciences (GILD), 2017–2018.
The 16 reported transactions were 6 tax withholdings, 5 stock awards, 3 option exercises and 1 option or other derivative award, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $510K and no sales.
The only open-market purchase was 30,000 shares of QNCX at an average $17.00 on May 13, 2019, about $510K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 13, 2019 | QNCX Quince Therapeutics, Inc. | Director | Buy | 30,000 | $17.00 | $510,000.00 | New |